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Background: Carotid artery stenting (CAS) and carotid endarterectomy (CEA) are alternative strategies for stroke prevention
in patients with atherosclerotic carotid disease. CEA has been considered the first-line treatment for carotid stenosis worldwide,
and the safety and efficacy of CAS compared to CEA remains in question.
Objective: The purpose of this study is to compare the practice and outcomes of CAS and CEA in a real-world setting within
public university hospitals in Brazil.
Methods: This study will be a prospective 5-year analysis of treatment for atherosclerotic carotid stenosis with CEA and CAS
performed at 5 centers affiliated with the Vascular Study Group at public university hospitals in Brazil. The indications for the
procedures will be determined by each surgeon’s individual discretion, in accordance with preoperative risk evaluation. The
primary outcome measures will be (1) any in-hospital stroke or death, and (2) any per-procedural stroke, death, or myocardial
infarction (MI). Patients undergoing CEA in conjunction with cardiac surgery will be excluded from the study. Multivariate
logistic regression will be performed to identify predictors of stroke or death in patients undergoing CEA and CAS. All tests of
significance will be performed at the .05 level. This study was approved by the Committee of Ethics in Research at the University
Hospital of Ribeirao Preto Medical School, and in all other participating institutions linked to National Research System and
National Board of Health in Brazil (Process 15695/2011).
Results: This study is currently in the recruitment phase, and the final patient is expected to be enrolled by the end of 2018. We
hope to recruit approximately 800 patients to the study. Analyses will focus on primary end points for patients that are allocated
to each treatment group. During the per-procedural period, the occurrence of the primary end point components (stroke, MI, or
death) for CAS and CEA will be analyzed for symptomatic or asymptomatic subjects.
Conclusions: The analyses of the primary endpoints (and all others variables of the study) are expected to be published in 2019
in a peer reviewed journal, and results will be presented at scientific meetings, with summary results published online. This study
will obtain new data related to the quality of treatment for carotid disease in Brazil at the primary training centers of future vascular
surgeons, but the initial data that will be obtained and published (with the outcomes and complications) are restricted to the first
30 days postprocedure. This time restriction limits the comparison of the results that relate to the main goal of treatment, which
is to decrease the risk of stroke over 5 years. The purpose of the study group is to continue the monitoring of patient records, and
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evaluate the follow-up data in the 5 years following the initial evaluation. This study protocol will contribute very significantly
to improving the care of patients with carotid disease, in addition to qualifying the level of assistance provided in public university
hospitals in the state of São Paulo, Brazil.
Trial Registration: Clinicaltrials.gov NCT02538276; https://www.clinicaltrials.gov/ct2/show/NCT02538276 (Archived by
WebCite at http://www.webcitation.org/6m7APnFLD)
(JMIR Res Protoc 2016;5(4):e226)   doi:10.2196/resprot.5986
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Introduction
Cerebrovascular disease is a leading cause of serious long-term
disability and death [1,2]. A significant proportion of ischemic
strokes originate from the atherosclerosis of extracranial arteries.
In most cases, carotid endarterectomy (CEA) or stent angioplasty
of the carotid bifurcation is considered when color duplex
ultrasound detects clinically significant extracranial internal
carotid artery stenosis. However, several clinical situations exist
in which other imaging techniques are needed to provide greater
anatomical detail and resolution.
Revascularization of severely atherosclerotic carotid arteries
has been shown to be safe and effective in the prevention of
stroke [2-5]. Carotid artery stenting (CAS) and CEA are two
alternative methods of revascularization, and these techniques
have been compared in small randomized clinical trials [6-10].
In the 2010 International Carotid Stenting Study (ICSS), 1713
symptomatic patients from 50 centers in Europe, Australia, New
Zealand, and Canada were prospectively randomized to a CAS
or CEA condition. The 30-day results showed a combined
stroke, death, and myocardial infarction (MI) rate of 7.4% for
CAS and 4.0% for CEA (P<.006). This effect was primarily
driven by an increased stroke rate of 7.0% for CAS versus 3.3%
for CEA [1].
Although randomized trials provide the most scientifically valid
comparisons between treatments, they do not reflect the diversity
of patients or technical proficiency present in broad
contemporary clinical practice. CEA has been considered the
first-line treatment for carotid stenosis worldwide, and the safety
and efficacy of CAS compared to CEA remains in question.
CAS is officially approved for use in multiple countries, and
the number of patients undergoing CAS has been increasing
due to its less-invasive nature. The present study aims to
demonstrate the real-world status of the treatment of carotid
artery disease with CAS and CEA using the prospective registry
of vascular diseases of university hospitals in the state of Sao
Paulo, Brazil, called the RHEUNI (Registry Project of Vascular
Disease in the Public University Hospitals of São Paulo). It is
well known that no prospective studies with a significant number
of cases concerning the treatment of carotid disease exist in
Brazil; all available data were derived from studies conducted
in other countries. Thus, the main objective of this study is to
evaluate the quality of treatment for carotid disease in Brazil
by analyzing the two main techniques currently available. The
data will be derived from the vascular surgery centers that bear
primary responsibility for the training of future vascular
surgeons.
Methods
Patient Population and Setting
The CEA and CAS registry in Brazil (part of RHEUNI) is being
used as a prospective observational study in Brazil, and has
been conducted since July 2013. Final data analyses are expected
in July 2018 from the 5 public university hospitals of the São
Paulo state that provide vascular therapy. Several consecutive
procedures will be registered as CEA or CAS by certified
vascular surgeons from 5 centers (University Hospital of
Ribeirão Preto Medical School of University of São Paulo,
University Hospital of School of Medical Sciences of University
of Campinas, University Hospital of Marilia Medical School,
University Hospital of Botucatu Medical School, and University
Hospital of São Jose do Rio Preto Medical School). All
participating vascular surgical centers have extensive experience
in the treatment of carotid disease, and they are all training
centers of reference in Brazil. The ethical committee of each
hospital has approved this project.
Inclusion criteria are as follows: patients with carotid
atherosclerotic stenosis >70% who underwent CEA or CAS for
the treatment of carotid stenosis at any of the 5 hospitals
involved in the study, male or female, and >18 years of age.
Carotid stenosis is defined as (1) stenosis >70% by catheter
angiography (North American Symptomatic Carotid
Endarterectomy Trial criteria) or (2) by Doppler ultrasound with
>70% stenosis defined by a peak systolic velocity of at least
230 cm/second, plus at least one of the following: an end
diastolic velocity >100 cm/second, or internal carotid/common
carotid artery peak systolic velocity ratio >4.0, or computer
tomography with >70% stenosis, or magnetic resonance with
>70% stenosis. Exclusion criteria include cases of concomitant
cardiac surgery, carotid dissection, fibromuscular dysplasia, or
trauma.
RHEUNI data have been validated for completeness by quarterly
audits of discharge claims data from each participating
institution. These audits ensure complete inclusion of all
consecutive procedures performed at the participating hospitals.
Data Collection
The recorded characteristics and backgrounds of patients who
undergo CAS and CEA will include: age, gender, and high-risk
CEA characteristics (according to the Stenting and Angioplasty
with Protection in Patients at High Risk for Endarterectomy
trial [6]). In addition, symptom presentation and the degree of
stenosis will be analyzed. Procedural success, antiplatelet use,
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embolic protection device (EPD) use, and the type of stent strut
(open-cell or closed-cell) or patch used for CEA will be
recorded, and the execution of prior post balloon dilatation at
CAS (and procedure-related complications) will be analyzed to
clarify the current strategy and the treatment results of both
techniques. The degrees of stenosis will be measured using the
method employed by the North American Symptomatic Carotid
Endarterectomy Trial [2].
Data Source and Measurement
Outcomes will be stratified by symptomatic and asymptomatic
status. Symptomatic patients will be defined as having a
neurological event, including any hemispheric or ocular transient
ischemic attack, or major or minor stroke, that precedes the
intervention ipsilateral to the treated lesion. Our definition of a
symptomatic patient is the occurrence of symptoms for up to
180 days. This definition is similar to that of the Carotid
Revascularization Stent Trial (CREST), although ICSS trial
lesions were considered symptomatic for up to one year
[1,11,12].
Technical success pertains to per-procedural events from the
initiation of the procedure through the first 24-hour post
operative period. Primary technical success will require the
successful excision of the carotid plaque by surgical or
interventional means. Technical success will be assessed by the
outcomes and complications related to preoperative carotid
angiograms, whenever these imaging studies are obtained prior
to the carotid intervention. For CEA, primary technical success
implies the successful removal of the carotid plaque and closure
of the artery, with or without a patch, with less than 30% residual
stenosis in the absence of stroke, MI, and death. For CAS, the
introduction and deployment of the EPD and carotid stent in
the absence of stroke, MI, death, surgical conversion, and
vascular obstruction constitute primary technical success [13].
Secondary endpoints of interest include procedure time, blood
loss, blood transfusion, clamping and shunting time, fluoroscopy
time, contrast load, recovery time, range and average number
of days in an intensive care unit, and length of hospital stay.
All complications will be categorized as local vascular, local
nonvascular, or systemic. Complications after carotid
interventions will be reported in a systematic and standardized
manner with a description of the degrees of severity. Although
assigning a degree of severity to all complications arising from
different treatment methods may be difficult, severity scales
should be provided whenever possible to allow for the
assessment and comparison of adverse events. The following
severity scale has been modified from the reporting standards
for lower extremity ischemia established by Rutherford et al
[14]: Mild (level 1) refers to a complication that resolves
spontaneously or with minimal intervention, does not increase
the length of hospital stay, and does not cause permanent
disability. Moderate (level 2) refers to the need for significant
intervention, an extension of hospitalization beyond 24 hours,
and, at most, minor permanent disability that does not interfere
with normal daily activity. A severe complication (level 3)
requires major surgical, endovascular, or medical intervention,
may be associated with prolonged convalescence, is usually
accompanied by prolonged or permanent disability, and may
result in death. Prehospital discharge data related to stroke/death
will be recorded, as applicable.
When obtaining patient consent, the patient will first be
approached by a doctor who is a member of the treatment team
at the same hospital in which the patient will be receiving
treatment. Upon obtaining patient consent, we will record the
patient name, patient signature, date of signature, and the name
of the doctor who introduced the study to the patient, as well
as his/her professional number and signature.
Researcher Responsibilities, Institutions, and Sponsors
The principal investigators are committed to continuing the
project over time while ensuring the accuracy of the information.
Data will be collected from the routine diagnostic tests and
specific treatment at each institution. There will be no project
sponsor external to the universities.
The recruitment information will be available from the
participating hospitals via an online document available to
participants. In addition, the analytical procedure will include
bimonthly meetings of the group of doctors responsible for the
study, along with the respective principal investigators, to
observe the progress of the project and evaluate the partial and
total data, in addition to writing the manuscript.
Statistical Analyses
Initial analyses will include sociodemographic characteristics
of patients undergoing CAS, and those referred for CEA. The
projected number of cases during the study period is
approximately 800. Categorical variables will be compared and
presented as percentages. Continuous variables will be compared
using analysis of variance and will be presented as means with
standard deviations. To identify patient characteristics that are
independently associated with a referral for CAS versus CEA,
no parsimonious multivariate logistic regression analysis of the
probability of undergoing CAS will be performed. All analyses
will be conducted using Microsoft Excel (Redmond, WA, USA)
and Epi-Info (Atlanta, GA, USA). All significance tests will be
performed at the .05 level.
Results
The study is in the recruitment phase, and we are enrolling
patients at 5 centers in Brazil. It is anticipated that 800 patients
will be recruited to the study by the end of 2018. Analyses will
focus on primary end points for patients that are allocated to
each treatment group. During the per-procedural period, the
occurrence of the primary end point components (stroke, MI,
or death) for CAS and CEA will be analyzed for symptomatic
or asymptomatic subjects. The median time from randomization
to the procedure will be compared for CAS and CEA. Stenting
with embolic protection of patients will be assigned to the CAS
group. General or local anesthesia of patients will be assigned
to the CEA group. The median duration of follow-up will be
determined. During that time, the level or prevalence of selected
risk factors will be analyzed to determine if they remained
similar between the two treatment groups.
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Clinical studies that evaluate carotid interventions, particularly
those that compare different treatment modalities, may be
difficult to interpret when differences in demographics,
comorbid conditions, and perioperative risk factors are not
identified and characterized [13,15].
The primary objective of the treatment for carotid stenosis is
the reduction of risks related to stroke and death. Therefore, the
primary outcome criteria for any carotid intervention include
the prevention of the following: (1) all per-procedural strokes
and death; (2) subsequent ipsilateral stroke; and (3) stroke or
death that may result from primary or secondary treatment.
There is agreement among health professionals that adequate
training and experience of vascular surgeons is an important
factor in maintaining the quality and outcomes of CAS or CEA,
and this issue has been discussed in many reports following the
results of European randomized controlled trials [16]. It has
been suggested that CAS and CEA surgeons select an optimal
strategy for each case, especially regarding protection methods,
in accordance with preoperative risk evaluation. One of the
major concerns associated with CAS is the potential for embolic
infarction during the procedure. Among other causes of plaque
components at the stenotic site, lipid core and plaque
hemorrhaging are highly associated with increasing incidents
of embolic infarction after CAS [17]. Multiple randomized trials
have compared CAS with CEA, with varying results. Variability
among the trials complicates efforts to make direct comparisons;
thus, determining the best treatment strategy for symptomatic
or asymptomatic patients is difficult.
One meta-analysis pooled data from 13 prospective, randomized,
or controlled clinical trials that compared CEA with CAS [18].
With combined data from all trials, over 7000 patients were
included, the majority of whom (79%) were symptomatic. The
post operative risk of stroke and death over the subsequent 30
days was higher in the CAS group compared with the CEA
group (odds ratio [OR] 1.57, P=.01) and was highest in
symptomatic patients (OR 1.89, P=.01). EPDs used with CAS
did not significantly reduce the 30-day per-procedural risk of
stroke/death related to CEA, but they did decrease the 30-day
risk of stroke/death compared to that associated with CAS
without an EPD (2.7% vs 7.5%, OR 0.34, P<.01). In contrast,
CAS was associated with a lower risk of cranial neuropathy
(OR 0.06, P<.01) and a lower risk of post operative MI (OR
0.43, P<.01). Based on these findings, the authors advocated
reserving CAS for revascularization in patients with anatomical
conditions that make CEA difficult or place patients at higher
risk for cranial nerve injury (such as restenosis after prior CEA),
or in patients with concomitant significant carotid artery disease.
The limitation of CAS to specific patient groups is outlined in
both the Society of Vascular Surgery and European Society of
Vascular Surgery guidelines, particularly for those at high risk
for CEA and in, “high-volume centers with documented low
per-procedural stroke and death rates or inside a randomized
clinical trial” [19,20].
Some other important studies are underway. In response to the
growing uncertainty regarding clinical management of
asymptomatic patients with carotid artery disease, the National
Institutes of Health is financing the CREST-2 trial. This
multicenter, randomized study has two arms related to
intervention: CEA versus best medical therapy (BMT) and CAS
versus BMT. Patients can opt to enroll in either the CEA or
CAS arm. Randomization, therefore, determines whether a
patient undergoes an intervention or BMT, rather than the type
of intervention (CEA or CAS). Patients allocated to CEA or
CAS treatments will also receive the same BMT as those
randomized to medical treatments. The study is expected to take
approximately 10 years to complete randomization, and produce
results for at least 4 years of follow-up [21].
The hospitals participating in this proposed study have a
common characteristic: specifically, each is a large public
university hospital involved in the training of new vascular
surgeons within the most densely populated state of Brazil. This
study, therefore, will represent a significant and ecologically
valid sample for the treatment of carotid atherosclerosis in
Brazil. Despite the existence of countless studies and
international records pertaining to treatment for carotid artery
disease, our study aims to obtain relevant data in the real-world
of medical care in public university hospitals that are training
future Brazilian vascular surgeons. Interactions between
professionals who specialize in treating neurovascular diseases
and vascular surgeons has become increasingly important in
the ongoing search for the best approach to treating carotid
disease, so the increased knowledge regarding the therapeutic
results that are obtained in each region or country is of
fundamental importance [22]. This knowledge will contribute
very significantly to improving care for patients with carotid
disease, in addition to qualifying the level of assistance provided
in public university hospitals in the state of São Paulo, Brazil.
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